That includes Lilly's Alzheimer's candidates, currently headed by amyloid-targeting drug donanemab which was ... facility for active pharmaceutical ingredients (APIs) in Dublin, creating 100 ...

(Bloomberg) — Lonza Group AG has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ingredients business, according to people familiar with the ...

that will be used to produce its new Alzheimer's therapy donanemab as well as other biologics, and AstraZeneca's recently opened, $360 million active pharmaceutical ingredient (API) facility in ...

Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have been ... Also, tirzepatide, the ingredient in Mounjaro and Zepbound, is being developed for other indications.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. Our independent committee said last year that the ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. We've funded research 30 years ago responsible for identifying the role of the amyloid ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...